Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy



Status:Terminated
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:5/18/2018
Start Date:October 11, 2010
End Date:December 19, 2016

Use our guide to learn which trials are right for you!

Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy

This was a multi-center, parallel, active comparator controlled, open-label, randomized (1:1)
phase III study of single agent ofatumumab compared to single agent rituximab in subjects
with rituximab-sensitive indolent B-cell non hodgkin lymphoma that has relapsed at least 6
months after completing treatment with single agent rituximab or a rituximab-containing
regimen. Subjects must have attained a Complete Response or Partial Response to their last
prior rituximab containing therapy lasting at least six months beyond the end of rituximab
therapy. Subjects were to receive four weekly doses of single agent ofatumumab (1000 mg) or
rituximab (375 mg/m2), followed by ofatumumab (1000 mg) or rituximab (375 mg/m2) every 2
months for four additional doses. Therefore, subjects were to receive a total of eight doses
of anti-CD20 antibody over 9 months. Subjects were evaluated for response after completion of
the first four doses of therapy, after six doses of therapy, and after completion of study
therapy. Subjects were to be followed until the end of the designated follow-up period (total
study duration of 200 weeks) or until they meet the withdrawal criteria.

The primary objective of the study OMB157D 2303 was to demonstrate the efficacy of Arzerra
based on the primary endpoint (Progression-free survival (PFS) as assessed by the IRC) in
patients with Indolent B-cell Non-Hodgkin's Lymphoma Relapsed After Rituximab-Containing
Regimen.

The Independent Data Monitoring Committee (IDMC) met on November 22, 2015 and recommended the
termination of the study due to futility (cut-off date = 12Jun2015). The IDMC reviewed
analyses results for progression free survival (PFS), overall response rate (ORR), and
overall survival (OS). Novartis accepted this recommendation and the study was closed.

Final analysis was performed (cut-off date =19 Dec 2016). As the study was stopped for
futility, the primary objective was not met and some secondary endpoints, supportive of
primary objective (Duration of Response (DOR), time to next therapy, and pharmacokinetics)
were removed as secondary end points.


Inclusion Criteria:

1. Indolent NHL subtypes defined according to World Health Organization guidelines:

1. Follicular lymphoma Grades 1, 2, 3 A

2. Small lymphocytic lymphoma (SLL)

3. Marginal zone lymphoma

4. Lymphoplasmacytic lymphoma

2. Rituximab-sensitive iNHL, defined as a partial or complete response to their last
prior treatment with rituximab or a rituximab-containing regimen lasting at least 6
months following completion of rituximab treatment.

3. Relapse or disease progression following response to prior rituximab-based therapy, as
defined by 2007 RRCML criteria, which requires therapy.

4. Radiographically measurable disease, defined as: 2 or more clearly demarcated
lesions/nodes with a long axis >1.5 cm and short axis ≥1.0cm. OR 1 clearly demarcated
lesion/node with a long axis >2.0 cm and short axis ≥1.0cm.

5. ECOG Performance Status of 0, 1, or 2.

6. Age ≥18 years.

7. Life expectancy of at least 6 months in the opinion of the investigator.

8. The patient or their legally acceptable representative must be capable of giving
written informed consent prior to performing any study-specific tests or procedures.

9. All prior treatment related non-hematologic toxicities (with the exception of
alopecia) must have resolved to CTCAE (Version 4.0) ≤ Grade 2 at the time of
randomization.

10. One or more of the following indications for treatment:

1. Cytopenias

2. One or more of the following lymphoma-related symptoms:

- Night sweats without signs of infection

- Unintentional weight loss (10% within the previous 6 months)

- Recurrent, unexplained fever of greater than 100.5F (38C) without signs of
infection

- Fatigue which interferes with the patient's quality of life

3. Progressive or massive lymphadenopathy OR

4. Progressive or massive organomegaly French subjects: In France, a subject will be
eligible for inclusion in this study only if either affiliated to or a
beneficiary of a social security category.

Exclusion Criteria:

1. Previous treatment with ofatumumab.

2. Previous anti-CD20 radioimmunotherapy (RIT) or non-rituximab anti-CD20 therapy (such
as obinutuzumab) within 6 months prior to randomization. Patients who have received
previous anti-CD20 RIT or non-rituximab anti-CD20 therapy (such as obinutuzumab) must
have attained a partial or complete response lasting at least 6 months, and must have
recovered from any hematologic or other toxicity.

3. Previous autologous stem cell transplantation within 6 months prior to randomization.

4. Previous allogeneic stem cell transplantation.

5. Previous anti-lymphoma monoclonal antibody therapy (excluding anti-CD20 therapy and
anti-CD20 RIT), chemotherapy, glucocorticoid, or other systemic therapy for lymphoma
within 3 months prior to randomization.

6. Current or previous participation in the treatment phase of another interventional
clinical study within 4 weeks prior to randomization. Patients may continue in the
follow-up phase of another interventional clinical study, but may not have undergone
any treatment on the other study within 4 weeks prior to randomization.

7. Current or previous other malignancy within 2 years prior to randomization. Subjects
who have been free of malignancy for at least 2 years, or have a history of completely
resected non-melanoma skin cancer or successfully treated carcinoma in situ, are
eligible.

8. Chronic or current active infectious disease requiring systemic antibiotics,
antifungal, or antiviral treatment such as, but not limited to, chronic renal
infection, chronic chest infection with bronchiectasis, tuberculosis, active Hepatitis
C, and known HIV disease. All HIV-positive patients are excluded from this study,
regardless of whether they have an Acquired Immunodeficiency Syndrome (AIDS) defining
disease and/or are on antiviral therapy. Prophylactic antiviral and/or antibacterial
antibiotics to prevent recurrence of previous infections are permitted.

9. Clinically significant cardiac disease as judged by the investigator including
unstable angina, acute myocardial infarction within 6 months prior to randomization,
uncontrolled congestive heart failure, and uncontrolled arrhythmia. Subjects with
congestive heart disease or arrhythmias such as atrial fibrillation whose cardiac
disease is well controlled on a stable medical regimen are eligible.

10. Other significant concurrent, uncontrolled medical conditions including, but not
limited to, renal, hepatic, autoimmune, hematological, gastrointestinal, endocrine,
pulmonary, neurological, cerebral or psychiatric disease which, in the investigator's
opinion, will impact study participation.

11. Screening laboratory values:

1. Neutrophils < 1.5 x 10^9/L (unless due to iNHL involvement of the bone marrow)

2. Platelets < 50 x 10^9/L (unless due to iNHL involvement of the bone marrow)

3. ALT or AST > 3 x ULN

4. Alkaline phosphatase > 1.5 x ULN (unless due to lymphoma or a non-malignant,
non-hepatic cause such as Paget's disease)

5. Total bilirubin > 1.5 x ULN (unless due to lymphoma or isolated, predominantly
indirect hyperbilirubinemia due to Gilbert's syndrome)

12. Known or suspected inability to fully comply with study protocol

13. Because the effects of ofatumumab on fetuses and nursing infants are not known, the
following are ineligible for study entry:

1. Lactating women.

2. Women with a positive pregnancy test at study entry.

3. Men with partners of childbearing potential and women of childbearing potential
who are not willing to use adequate contraception from study entry through one
year following last treatment dose. (Adequate contraception is defined as
abstinence, oral hormonal birth control, hormonal birth control injections,
implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive
patches, intrauterine device, and male partner sterilization if male partner is
the sole partner for a female subject. The double barrier method can be used in
regions where considered acceptable and adequate, defined as condom or occlusive
cap plus spermicidal agent).

14. Current active liver or biliary disease (with the exception of Gilbert's syndrome or
asymptomatic gallstones).

15. Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In
addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB
DNA test will be performed and if positive the subject will be excluded.
We found this trial at
72
sites
Chattanooga, Tennessee 37404
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Albuquerque, New Mexico 87108
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Albuquerque, New Mexico 87108
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Ames, Iowa 50010
?
mi
from
Ames, IA
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anderson, Indiana 46016
?
mi
from
Anderson, IN
Click here to add this to my saved trials
?
mi
from
Antwerpen,
Click here to add this to my saved trials
Bismarck, North Dakota 58501
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
Bozeman, Montana 59718
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
Canton, Ohio 44718
?
mi
from
Canton, OH
Click here to add this to my saved trials
Canton, Ohio 44718
?
mi
from
Canton, OH
Click here to add this to my saved trials
Columbia, Missouri 65212
?
mi
from
Columbia, MO
Click here to add this to my saved trials
Danville, Pennsylvania 17822
?
mi
from
Danville, PA
Click here to add this to my saved trials
Ephrata, Pennsylvania 17522
?
mi
from
Ephrata, PA
Click here to add this to my saved trials
Evanston, Illinois 60201
?
mi
from
Evanston, IL
Click here to add this to my saved trials
Fort Sam Houston, Texas 78234
?
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
Fredericksburg, Virginia 22401
?
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Germantown, Tennessee 38138
?
mi
from
Germantown, TN
Click here to add this to my saved trials
Gilbert, Arizona 85234
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Greenbrae, California 94904
?
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Greensboro, North Carolina 27401
?
mi
from
Greensboro, NC
Click here to add this to my saved trials
Hot Springs, Arkansas 71913
?
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Indianapolis, Indiana 46202
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Jackson, Mississippi 39209
?
mi
from
Jackson, MS
Click here to add this to my saved trials
Kalamazoo, Michigan 49048
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Kansas City, Missouri 64111
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Kennewick, Washington 99336
?
mi
from
Kennewick, WA
Click here to add this to my saved trials
Kirkland, Washington 98034
?
mi
from
Kirkland, WA
Click here to add this to my saved trials
Knoxville, Tennessee 37934
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Lake Success, New York 10042
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
Lakeland, Florida 33805
?
mi
from
Lakeland, FL
Click here to add this to my saved trials
Lancaster, Pennsylvania 17603
?
mi
from
Lancaster, PA
Click here to add this to my saved trials
Lincoln, Nebraska 68506
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
Lincoln, Nebraska 68506
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
Macon, Georgia 31201
?
mi
from
Macon, GA
Click here to add this to my saved trials
Marietta, Georgia 30060
?
mi
from
Marietta, GA
Click here to add this to my saved trials
Metairie, Louisiana 70006
?
mi
from
Metairie, LA
Click here to add this to my saved trials
Monterey, California 93940
?
mi
from
Monterey, CA
Click here to add this to my saved trials
Mount Kisco, New York 10549
?
mi
from
Mount Kisco, NY
Click here to add this to my saved trials
Mount Sterling, Kentucky 40353
?
mi
from
Mount Sterling, KY
Click here to add this to my saved trials
Mount Vernon, Washington 98273
?
mi
from
Mount Vernon, WA
Click here to add this to my saved trials
New Milford, Connecticut 06776
?
mi
from
New Milford, CT
Click here to add this to my saved trials
Ogden, Utah 84405
?
mi
from
Ogden, UT
Click here to add this to my saved trials
Orlando, Florida 32806
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Pembroke Pines, Florida 33024
?
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Peoria, Illinois 61615
?
mi
from
Peoria, IL
Click here to add this to my saved trials
Pleasant Hill, California 94523
?
mi
from
Pleasant Hill, CA
Click here to add this to my saved trials
Port Saint Lucie, Florida 34952
?
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
Portland, Oregon 97228
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Quincy, Illinois 62301
?
mi
from
Quincy, IL
Click here to add this to my saved trials
Rancho Mirage, California 92270
?
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
Saint Joseph, Missouri 64506
?
mi
from
Saint Joseph, MO
Click here to add this to my saved trials
Salinas, California 93901
?
mi
from
Salinas, CA
Click here to add this to my saved trials
Salt Lake City, Utah 84103
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Diego, California 92123
?
mi
from
San Diego, CA
Click here to add this to my saved trials
San Pablo, California 94806
?
mi
from
San Pablo, CA
Click here to add this to my saved trials
Santa Monica, California 90404
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Seattle, Washington 98103
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Seattle, Washington 98103
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Sequim, Washington 98382
?
mi
from
Sequim, WA
Click here to add this to my saved trials
Shreveport, Louisiana 71101
?
mi
from
Shreveport, LA
Click here to add this to my saved trials
Silver Spring, Maryland 20901
?
mi
from
Silver Spring, MD
Click here to add this to my saved trials
Skokie, Illinois 60077
?
mi
from
Skokie, IL
Click here to add this to my saved trials
Skokie, Illinois 60077
?
mi
from
Skokie, IL
Click here to add this to my saved trials
Spokane, Washington 99202
?
mi
from
Spokane, WA
Click here to add this to my saved trials
Springfield, Missouri 65804
?
mi
from
Springfield, MO
Click here to add this to my saved trials
Torrington, Connecticut 06790
?
mi
from
Torrington, CT
Click here to add this to my saved trials
Waterville, Maine 04901
?
mi
from
Waterville, ME
Click here to add this to my saved trials
West Palm Beach, Florida 33407
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Willow Grove, Pennsylvania 19090
?
mi
from
Willow Grove, PA
Click here to add this to my saved trials